Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Survivin Vaccine in Multiple Myeloma
NCT02851056Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2016
- Primary completion
- Jul 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dendritic cell survivin vaccine in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Primary endpoints: Rate of Complete Response at 90 days and Treatment Emergent Adverse Events at 6 months. Started Sep 2016; status: completed.
02
Drugs
dendritic cell survivin vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02851056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02851056.